New York Post
@nypost·2.4M subscribers·43.2K videos
New WeightWatchers deal gives dieters access to Ozempic | New York Post
Posted
March 8, 2023
Views
1,009
Likes
3
Comments
4
Engagement
0.69%
March 8, 2023
1,009
3
4
0.69%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
0:37Now PlayingWeightWatchers is taking a bite out of the weight-loss drug and telehealth industries.
The weight-loss program — also known as WW International — is set to purchase the company Sequence.
Sequence, a telehealth and medical subscription service, links patients with doctors who can prescribe them controversial weight-loss and diabetes drugs, such as Ozempic, Wegovy and Mounjaro. The company also offers access to fitness coaches and dietitians to help them craft personal weight loss plans. WW will promote Sequence’s services to its members and the deal will enable them to incorporate weight-loss drugs as part of its existing diet, fitness and lifestyle offerings.
Executives unveiled the $132 million deal earlier this week.
“As science advances rapidly, we know there is a significant opportunity to improve outcomes for those using medications,” WeightWatchers CEO Sima Sistani said in a statement.
Read more at
#health #weightwatchers #ozempic
The New York Post is your source for breaking news, news about New York, sports, business, entertainment, opinion, real estate, culture, fashion, and more.
Subscribe to New York Post Sports
Catch the latest news here
Follow The New York Post on:
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
